about
Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate bindingStructural aspects of binding of α-linked digalactosides to human galectin-1Structural features for α-galactomannan binding to galectin-1.Identification and Validation of Sensory-Active Compounds from Data-Driven Research: A Flavoromics Approach.Lactose binding to human galectin-7 (p53-induced gene 1) induces long-range effects through the protein resulting in increased dimer stability and evidence for positive cooperativity.Binding of polysaccharides to human galectin-3 at a noncanonical site in its carbohydrate recognition domain.Intra- and intermolecular interactions of human galectin-3: assessment by full-assignment-based NMRStructural significance of galectin design: impairment of homodimer stability by linker insertion and partial reversion by ligand presence.Defining the potential of aglycone modifications for affinity/selectivity enhancement against medically relevant lectins: synthesis, activity screening, and HSQC-based NMR analysis.Novel polysaccharide binding to the N-terminal tail of galectin-3 is likely modulated by proline isomerization.Chemokines from a Structural Perspective.Macromolecular assemblies of complex polysaccharides with galectin-3 and their synergistic effects on function.Adhesion/growth-regulatory galectins tested in combination: evidence for formation of hybrids as heterodimers.Galectins as Molecular Targets for Therapeutic Intervention.1H, 13C, and 15N backbone and side-chain chemical shift assignments for the 36 proline-containing, full length 29 kDa human chimera-type galectin-31H, 13C, and 15N backbone and side-chain chemical shift assignments for the 31 kDa human galectin-7 (p53-induced gene 1) homodimer, a pro-apoptotic lectin
P50
Q34564173-03BF4145-B7A1-42F5-A2CC-94D578CF98A3Q35559685-8518D102-C63E-4BCC-B967-C9922E5CD9BAQ35779469-B8386930-9644-4E12-B5E0-21739C04E9E6Q36376573-0EAF0ABA-3968-4058-9DD7-A6384D47FB62Q36716840-2B9CAA93-C809-49D0-A473-64F7A0D0E73FQ40232517-79513F3F-AFD1-43D1-AF27-0129F9A41E27Q41058851-75F75274-70EC-4693-ADA3-6B0BECD704F3Q41183639-481E4A7E-4C78-452F-87FE-420C14A0FFD7Q45988156-13B7E6F5-777B-45FF-A6BA-5679C5C580CBQ46296067-754C3138-45CE-4858-934F-1AA352DDC1D8Q47154563-C4633727-3653-451D-A620-3C169E93D264Q47684685-5F492214-0262-4E19-9163-DF9A4D7277EEQ50102103-AB5B0F52-83E9-480B-AC32-EDA1F3E559A3Q55316400-7EE0F95C-98D0-4540-B9D1-49713D43467BQ62620238-3C1A183E-C945-4FBF-9230-E3B4ABB016D5Q62620606-B0861EC4-F24A-4671-8A93-988AD525830D
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Michelle C Miller
@ast
Michelle C Miller
@en
Michelle C Miller
@es
Michelle C Miller
@nl
type
label
Michelle C Miller
@ast
Michelle C Miller
@en
Michelle C Miller
@es
Michelle C Miller
@nl
prefLabel
Michelle C Miller
@ast
Michelle C Miller
@en
Michelle C Miller
@es
Michelle C Miller
@nl
P106
P1153
26639591200
P21
P31
P496
0000-0002-7860-5785